Expenses have surged for Louisiana’s public worker health insurance plans as more people are prescribed GLP-1 drugs, known by brand names such as Ozempic and Mounjaro. Over the past six years, GLP-1 drugs have replaced Metformin, a cheaper, but sometimes less effective, Type 2 diabetes drug. The U.S. Food and Drug Administration warned earlier this month against using compounded versions of GLP-1 drugs however. However, compounded drugs are not FDA approved,” the agency said in a statement released Sept. 5. Such compounded versions are already used broadly in the public because the medications’ costs are high and insurance coverage is limited.